Hanmi Pharm Reports 2Q Sales of 378.1 Billion KRW and 75% Increase in Operating Profit... "Expecting Record High Performance"

Hanmi Pharm announced on the 30th that it recorded consolidated sales of KRW 378.133 billion and operating profit of KRW 58.19 billion in the second quarter of this year. Compared to the same period last year, sales increased by 10.3%, and operating profit surged by an impressive 75.3%.

On a cumulative basis for the first half of the year, consolidated sales reached KRW 781.8 billion, and operating profit was KRW 134.8 billion, showing growth of 11.1% and 44.8%, respectively. The company stated, "We expect to achieve the highest sales performance since our founding again this year," and added, "Thanks to strong sales of key domestic and international products and the growth of subsidiaries, we have achieved outstanding results that once again exceeded market expectations." In particular, they emphasized, "Operating profit rose sharply due to the continuous sales growth of improved and combination new drugs," and "As a result, net profit also surged." Hanmi Pharm's net profit for the second quarter was KRW 46.988 billion, an increase of 150.6% compared to the same period last year.

It is especially noted that domestic prescription drug performance solidly drove sales growth. Hanmi Pharm has maintained the number one position in domestic prescription sales for six consecutive years. The flagship product, the dyslipidemia treatment Rosuzet, surpassed KRW 100 billion in cumulative outpatient prescription sales in the first half of the year. In the second quarter alone, it recorded KRW 51.1 billion, a 16.6% increase compared to the same period last year. The Amozaltan family, a group of combination drugs for hypertension treatment, also posted sales of KRW 36.2 billion in the second quarter.

Overseas business also continued its growth trend. Hanmi Pharm’s key overseas subsidiary in China, Beijing Hanmi Pharm, recorded consolidated sales of KRW 98.7 billion and operating profit of KRW 25.2 billion in the second quarter. Compared to the same period last year, sales increased by 9.6%, and operating profit rose by 15.0%. Despite the seasonal off-season, constipation drug Litong and adult tonic Maechangan maintained solid performance with sales increasing by 21.6% and 23.4%, respectively, compared to the same period last year. Additionally, Hanmi Pharm’s export sales also grew by 5.9% year-on-year to KRW 57.8 billion on a separate basis in the second quarter.

Park Jae-hyun, CEO of Hanmi Pharm, said, “Hanmi’s robust research and development (R&D) capabilities and the excellent product quality of our self-developed drugs are driving sustainable growth,” adding, "In the second half of the year, clinical results of major new drug pipelines are scheduled to be announced, and as we accelerate research beyond targeted anticancer drugs to immune anticancer drug development, we will further fulfill our role as a leading pharmaceutical company representing Korea.” Hanmi Pharm invested KRW 98.875 billion in R&D on a consolidated basis in the first half alone, spending about 12.6% of sales on R&D expenses.

This content was produced with the assistance of AI translation services.